Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on the a) number, b) biological sex and c) age of people entering the puberty blockers to date.

As with all clinical trials, the PATHWAYS trial is subject to the reporting requirements set out in the International Council for Harmonisation Good Clinical Practice standards, and to the requirements provided under The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025.

The research team on the trial is currently working to complete the set-up of the study prior to the start of recruitment. Once under way, the research team will work closely with the advisory boards and other stakeholders to ensure all their findings are accessible and clearly communicated to patients, families, and the general public, alongside dissemination to the scientific community and policy makers.

There is no current plan to publish detailed breakdowns of the trial cohort as suggested by the Hon. Member, in order to protect the safety and anonymity of participants. However, an independent Data Monitoring and Ethics Committee will uphold the safety, rights, and well-being of the study participants and consider the need for any interim analysis.